Literature DB >> 19082778

Comparison of osteoclast precursors in peripheral blood mononuclear cells from rheumatoid arthritis and osteoporosis patients.

Michinari Nose1, Hidetoshi Yamazaki, Hiroshi Hagino, Yasuo Morio, Shin-Ichi Hayashi, Ryota Teshima.   

Abstract

Osteolytic disorders cause serious problems for quality of life with aging. Osteolysis is performed by osteoclasts of the hematopoietic lineage that share some characteristics with monocytes and macrophages. As osteoclast precursors (pOCs) are present in peripheral blood, their characterization in osteolytic diseases may help us to understand risk factors. Although essential factors for osteoclastogenesis have been reported, the effective induction from pOCs in human peripheral blood mononuclear cells (PBMCs) to mature osteoclasts in culture requires further improvement. The aim of this study was development of an efficient culture system for human osteoclastogenesis and providing a simple system for the enrichment of pOCs from PBMCs. We employed coculturing of human PBMCs with a mouse stromal cell line. Significant numbers of tartrate-resistant acid phosphatase-positive (TRAP(+)) multinucleated osteoclasts (MNCs), which could resorb dentine slices, were efficiently induced in this culture condition. pOCs were enriched in an anti-CD16 antibody column-passed anti-CD14 antibody-bound cell population isolated by magnetic cell sorting. We compared the percentage of the CD14(high) CD16(dull) cell population, which mainly contained pOCs in PBMCs, from age-matched patients with rheumatoid arthritis (RA) and osteoporosis (OP), but it was comparable. However, the mean number of TRAP(+) MNCs generated in cultures from PBMCs of RA was higher. In contrast, the frequency of pOCs in PBMCs from OP was relatively higher. These results suggest the characteristics of pOCs from RA and OP may be different, because single pOCs from OP gave rise to lower numbers of osteoclasts than those from RA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082778     DOI: 10.1007/s00774-008-0011-0

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  44 in total

1.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

Review 2.  Therapeutic approaches to bone diseases.

Authors:  G A Rodan; T J Martin
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

Review 3.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

4.  The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

Authors:  N Udagawa; N Takahashi; T Akatsu; T Sasaki; A Yamaguchi; H Kodama; T J Martin; T Suda
Journal:  Endocrinology       Date:  1989-10       Impact factor: 4.736

Review 5.  Rheumatic diseases: the effects of inflammation on bone.

Authors:  Nicole C Walsh; Tania N Crotti; Steven R Goldring; Ellen M Gravallese
Journal:  Immunol Rev       Date:  2005-12       Impact factor: 12.988

6.  Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.

Authors:  Charlotte Swanson; Mattias Lorentzon; H Herschel Conaway; Ulf H Lerner
Journal:  Endocrinology       Date:  2006-04-13       Impact factor: 4.736

7.  Stromal cell-mediated stimulation of osteoclastogenesis.

Authors:  N Shevde; P Anklesaria; J S Greenberger; I Bleiberg; J Glowacki
Journal:  Proc Soc Exp Biol Med       Date:  1994-04

8.  Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.

Authors:  C R Yang; J H Wang; S L Hsieh; S M Wang; T L Hsu; W W Lin
Journal:  Cell Death Differ       Date:  2004-07       Impact factor: 15.828

9.  Chemically modified tetracyclines act through multiple mechanisms directly on osteoclast precursors.

Authors:  S G Holmes; K Still; D J Buttle; N J Bishop; P S Grabowski
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

10.  Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts.

Authors:  Yukiko Komano; Toshihiro Nanki; Kenji Hayashida; Ken Taniguchi; Nobuyuki Miyasaka
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

View more
  6 in total

Review 1.  Circulating monocytes: an appropriate model for bone-related study.

Authors:  Y Zhou; H-W Deng; H Shen
Journal:  Osteoporos Int       Date:  2015-07-21       Impact factor: 4.507

2.  High-fat diet causes bone loss in young mice by promoting osteoclastogenesis through alteration of the bone marrow environment.

Authors:  Lei Shu; Eric Beier; Tzong Sheu; Hengwei Zhang; Michael J Zuscik; Edward J Puzas; Brendan F Boyce; Robert A Mooney; Lianping Xing
Journal:  Calcif Tissue Int       Date:  2015-02-13       Impact factor: 4.333

3.  Soluble CD14 and fracture risk.

Authors:  M Bethel; P Bůžková; H A Fink; J A Robbins; J A Cauley; J Lee; J I Barzilay; D I Jalal; L D Carbone
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

4.  RANKL induces heterogeneous DC-STAMP(lo) and DC-STAMP(hi) osteoclast precursors of which the DC-STAMP(lo) precursors are the master fusogens.

Authors:  Kofi A Mensah; Christopher T Ritchlin; Edward M Schwarz
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

5.  Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1.

Authors:  Xiaoqing Zhu; Yinghua Zhao; Yuxue Jiang; Tianxue Qin; Jintong Chen; Xiao Chu; Qing Yi; Sujun Gao; Siqing Wang
Journal:  Oncotarget       Date:  2017-06-08

6.  Mendelian Randomization Identifies CpG Methylation Sites With Mediation Effects for Genetic Influences on BMD in Peripheral Blood Monocytes.

Authors:  Fangtang Yu; Chuan Qiu; Chao Xu; Qing Tian; Lan-Juan Zhao; Li Wu; Hong-Wen Deng; Hui Shen
Journal:  Front Genet       Date:  2020-02-28       Impact factor: 4.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.